Year: 2018
Type: article
Authors: Nancy R. Cook, Samia Mora, Paul M Ridker
Institutions: Brigham and Women's Hospital, Harvard University
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: U.S. Department of Health and Human Services, Donald W. Reynolds Foundation, American Heart Association, Amgen, Pfizer, AstraZeneca, Sanofi, Brigham and Women's Hospital, Teva Pharmaceutical Industries, Quest Diagnostics, Kowa Company, Fondation Leducq, National Institutes of Health, National Heart, Lung, and Blood Institute, National Cancer Institute, National Institute of Diabetes and Digestive and Kidney Diseases
Awards: G1050918383, G1471908156, G1528515809, G1851278524, G1986629506, G2103579298, Novel Applications of Risk Reclassification Methods in CVD Risk Prediction, G2209176514, G2239996411, G3062349281, G3069585042, G3219722387, Total plasma and IgG glycomes, statin therapy and ASCVD events, G3643850837, G3900787601, Reducing Inflammation for the Prevention of CVD: A Focus on Eicosanoid Pathways, G4221524492, G4282019567, G4502172849, G4546180501, G4673281338, G5178366675, G6694253514, TRIAL OF ASPIRIN AND VITAMIN E IN WOMEN, G700120080, G7332203415, G7430426612, G757750085, Women's Health Study: Continued Follow-up, G8606882599, Mentored Patient-Oriented Research for Preventing ASCVD Events, G915959914, Circulating plasma metabolites, diet, and risk of type 2 diabetes
OpenAlex ID: W2866063989
